The Washington Times

U.S. Food And Drug Administration

Latest U.S. Food And Drug Administration Items
  • Pharmacy industry sees HGH sales grow despite crackdown

    A federal crackdown on illicit foreign supplies of human growth hormone has failed to stop rampant misuse, and instead has driven record sales of the drug by some of the world's biggest pharmaceutical companies, an Associated Press investigation shows.


  • Ranbaxy recalls generic Lipitor doses

    Ranbaxy Pharmaceuticals Inc. has recalled dozens of lots of its generic version of cholesterol drug Lipitor because some may contain tiny glass particles, the latest in a string of manufacturing deficiencies that once led U.S. regulators to bar imports of the Indian company's medicines.


  • Layoffs at firm tied to Mass. pharmacy in outbreak

    A Massachusetts company with the same founders as a pharmacy tied to a deadly meningitis outbreak said Thursday it is laying off nearly all its employees amid a prolonged closure for inspection.


  • Mass. pharmacy dodged reprimand after protest

    Massachusetts regulators in 2004 proposed a formal reprimand for a company now linked to deadly meningitis outbreak, but they never delivered it after the company protested the reprimand could be "fatal to the business."


  • Mass. gov: Drug firm may have misled regulators

    The specialty pharmacy linked to a deadly meningitis outbreak may have misled regulators and done work beyond the scope of its state license, Massachusetts Gov. Deval Patrick said Wednesday.


  • Key dates in history of thalidomide

    1946_ Gruenenthal, a German pharmaceutical, is founded in Stolberg.


  • Bristol-Myers ends hepatitis C drug development

    Drugmaker Bristol-Myers Squibb Co. has scrapped a potential hepatitis C treatment after a patient participating in a test of the drug died of heart failure.


  • J&J removing harsh chemicals from products by 2015

    Johnson & Johnson plans to remove trace amounts of potentially cancer-causing and other dangerous chemicals from nearly all its adult toiletries and cosmetic products worldwide within 3 1/2 years.


  • EU approves Afinitor for certain breast cancers

    Swiss drug maker Novartis AG says it has received European approval to market Afinitor for treatment of women with the most common form of advanced breast cancer.


Happening Now